Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Patient-reported outcomes in metastatic castration-resistant prostate cancer

Nature Reviews Clinical Oncology volume 13, pages 643–650 (2016)Cite this article

Subjects

Abstract

Many novel therapies are available for use in patients with metastatic castration-resistant prostate cancer (mCRPC), some of which convey substantial progression-free survival and overall survival benefits. Delaying disease progression and providing palliation of symptoms are primary therapeutic aims of treating patients with mCRPC; therefore, ensuring that the benefit-to-harm ratios are acceptable to patients, through systematic measurement of patient-reported outcomes (PROs) using validated tools, is vital. In this Perspectives, we appraised the published reports from clinical trials testing treatments of mCRPC over the past 5 years and found that PROs were either not being measured routinely, or if used, were often not reported adequately, thus hampering evaluation of the true effects of many of these treatments on patients' quality of life. Improvements are needed because data collected directly from patients, not just physician-collected safety data and adverse events, are crucial to inform clinical decision-making on treatment options.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. [No authors listed.] Prostate cancer mortality in Europe and worldwide. Cancer Research UK http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/mortality#heading-Three (2016).

  2. de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).

    Article  CAS  Google Scholar 

  3. Berthold, D. R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26, 242–245 (2008).

    Article  CAS  Google Scholar 

  4. Parker, C. C. et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur. Urol. 63, 189–197 (2013).

    Article  CAS  Google Scholar 

  5. Kantoff, P. & Higano, C. S. Integration of immunotherapy into the management of advanced prostate cancer. Urol. Oncol. 30, S41–S47 (2012).

    Article  Google Scholar 

  6. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

    Article  CAS  Google Scholar 

  7. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).

    Article  CAS  Google Scholar 

  8. Ryan, C. J. et al. Randomized phase 3 trial of abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).

    Article  CAS  Google Scholar 

  9. Beer, T. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424–433 (2014).

    Article  Google Scholar 

  10. Atkinson, T. M. et al. Reliability of adverse symptom event reporting by clinicians. Qual. Life Res. 21, 1159–1164 (2012).

    Article  Google Scholar 

  11. Basch, E. 'The missing voice of patients in drug-safety reporting'. N. Engl. J. Med. 362, 865–869 (2010).

    Article  CAS  Google Scholar 

  12. Turner, S. Maher, E. J. Young, T. Young, J. & Vaughan Hudson, G. What are the information priorities for cancer patients involved in treatment decisions? An experienced surrogate study in Hodgkin's disease. Br. J. Cancer 73, 222–227 (1996).

    Article  CAS  Google Scholar 

  13. Bryant-Lukosius, D. et al. Evaluating health-related quality of life and priority health problems in patients with prostate cancer: a strategy for defining the role of the advanced practice nurse. Can. Oncol. Nurs. J. 20, 5–14 (2010).

    Article  Google Scholar 

  14. Moul, J. W. & Dawson, N. Quality of life associated with treatment of castration resistant prostate cancer: a review opf the literature. Cancer Invest. 30, 1–12 (2012).

    Article  Google Scholar 

  15. Ellis, L. M et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. 32, 1277–1280 (2014).

  16. Cherny, N. I. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann. Oncol. 26, 1547–1573 (2015).

    Article  CAS  Google Scholar 

  17. US Department of Health and Human Services. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labelling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (2009).

  18. European Medicines Agency, Committee for Medicinal Products for Human Use. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/04/WC500205159.pdf (2016).

  19. Vodicka, E. et al. Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials. gov (2007–2013). Contemp. Clin. Trials 43, 1–9 (2015).

    Article  CAS  Google Scholar 

  20. Calvert, M. et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309, 814–822 (2013).

    Article  CAS  Google Scholar 

  21. Scher, H. et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J. Clin. Oncol. 34, 1402–1418 (2016).

    Article  Google Scholar 

  22. Fizazi, K. et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 15, 1147–1156 (2014).

    Article  CAS  Google Scholar 

  23. Cella, D. et al. Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. Ann. Oncol. 26, 179–185 (2015).

    Article  CAS  Google Scholar 

  24. Loriot, Y. et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 16, 509–521 (2015).

    Article  CAS  Google Scholar 

  25. Logothetis, C. J. et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 13, 1210–1217 (2012).

    Article  CAS  Google Scholar 

  26. Harland, S. et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur. J. Cancer 49, 3648–3657 (2013).

    Article  CAS  Google Scholar 

  27. Sternberg, C. N. et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann. Oncol. 24, 1017–1025 (2013).

    Article  CAS  Google Scholar 

  28. Basch, E. et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 14, 1193–1199 (2013).

    Article  CAS  Google Scholar 

  29. Caffo, O. et al. Impact of docetaxel-based chemotherapy on quality of life of patients with castration resistant prostate cancer: results from a prospective phase II randomized trial. BJU Int. 108, 1825–1832 (2011).

    Article  CAS  Google Scholar 

  30. Caffo, O. et al. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. Future Oncol. 11, 1845–1845 (2015).

    Article  CAS  Google Scholar 

  31. Bahl, A. et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann. Oncol. 24, 2402–2408 (2013).

    Article  CAS  Google Scholar 

  32. Bahl, A. et al. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). BJU Int. 116, 880–887 (2015).

    Article  CAS  Google Scholar 

  33. Nilsson, S. et al. A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur. J. Cancer 48, 678–686 (2012).

    Article  CAS  Google Scholar 

  34. Agarwal, K.,K. Singla, S., Arora, G. & Bal, C. 177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur. J. Nucl. Med. Mol. Imaging 42, 79–88 (2015).

    Article  CAS  Google Scholar 

  35. von Moos, R. et al. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer 21, 3497–3507 (2013).

    Article  Google Scholar 

  36. Gater, A. B. et al. Pain in castration-resistant prostate cancer with bone metastases: a qualitative study. Health Qual. Life Outcomes 9, 88 (2011).

    Article  Google Scholar 

  37. Autio, K. A. et al. Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. J. Oncol. Pract. 9, 223–229 (2013).

    Article  Google Scholar 

  38. DeMuro, C. et al. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010. Value Health 15, 443–448 (2012).

    Article  Google Scholar 

  39. Chen, R. C. et al. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. J. Natl Cancer Inst. 106, 1–7 (2014).

    Article  Google Scholar 

  40. Morgans, A. K. et al. Development of a standardized set of patient-centered outcomes for advanced prostate cancer: an international effort for a unified approach. Eur. Urol. 68, 891–898 (2015).

    Article  Google Scholar 

  41. Szende, A. Oppe, M. & Devlin, N. EQ-5D Value Sets: Inventory, Comparative Review and User Guide (Springer, 2007).

    Book  Google Scholar 

  42. Aaronsson, N. K. et al. The European Organisation for Research and Treatment of Cancer QLQ C-30: a quality of life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85, 365–376 (1993).

    Article  Google Scholar 

  43. Borghede, G. & Sullivan, M. Measurement of quality of life in localised prostatic cancer patient treated with radiotherapy: development of a prostate cancer specific module supplementing the EORTC QLQ-C30. Qual. Life Res. 5, 212–222 (1996).

    Article  CAS  Google Scholar 

  44. Esper, P. et al. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument. Urology 50, 920–928 (1997).

    Article  CAS  Google Scholar 

  45. Cleeland, C. S. & Ryan, K. M. Pain assessment: global use of the Brief Pain Inventory. Ann. Acad. Med. Singapore 23, 129–138 (1994).

    CAS  PubMed  Google Scholar 

  46. Melzack, R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1, 277–299 (1975).

    Article  CAS  Google Scholar 

  47. McCaffery, M. & Pasero, C. Pain: clinical manual. J. Clin. Nursing 9, 650 (2000).

    Google Scholar 

  48. Mendoza, T. R. et al. The rapid assessment of fatigue in cancer patients: use of the brief fatigue inventory. 5, 1186–1196 (1999).

Download references

Author information

Authors and Affiliations

  1. Lesley J. Fallowfield and Valerie Jenkins are at the Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, East Sussex BN1 9RX, UK.,

    Lesley Fallowfield & Valerie Jenkins

  2. Heather Payne is at the Department of Oncology, University College Hospital, 235 Euston Road, London NW1 2BU, UK.,

    Heather Payne

Authors
  1. Lesley Fallowfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heather Payne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valerie Jenkins
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

V.J. and L.F. researched data for this article, all authors made a substantial contribution to discussions of content, V.J. and L.F. wrote the manuscript and all authors made a substantial contribution to reviewing and/or editing the manuscript prior to submission.

Corresponding author

Correspondence to Lesley Fallowfield.

Ethics declarations

Competing interests

L.F. has acted as a consultant for and received honoraria from Amgen, Astellas and Sanofi. The other authors declare no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fallowfield, L., Payne, H. & Jenkins, V. Patient-reported outcomes in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 13, 643–650 (2016). https://doi.org/10.1038/nrclinonc.2016.100

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.100

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing